Hartmut Hengel

The paper identifies gH/UL116 as a target for antibodies that neutralize HCMV and activate FcγR, showing its potential as a vaccine candidate.

This study identifies a second murine CMV vFcR, fcr-2, encoded by m119-118, which cooperates with fcr-1 to inhibit host Fc receptor activation and enhance viral pathogenesis.

This study uses cryo-EM to analyze antibodies targeting HCMV glycoproteins, identifying synergistic combinations that enhance neutralization.

This study shows HSV infection increases ALS risk and promotes TDP-43 pathology through ICP0-mediated disruption of PML bodies.

This paper engineers IgG1 antibodies with modified Fc domains to resist viral Fc receptor binding, enhancing NK cell activation and reducing HCMV spread in infected cells.

This study identifies which Fcγ-receptors respond to CRP isoforms and shows that pCRP* is the main activator, differing from IgG-Fc interactions.

This study identifies and characterizes Rhesus CMV-encoded Fcγ-binding glycoproteins, showing they delay antibody-mediated immune control during primary infection.